Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Under Investigation By Oregon For Deceptive Promotions

This article was originally published in The Pink Sheet Daily

Executive Summary

State effort is focused on one unnamed drug but may expand; the company is already facing a federal inquiry about off-label promotion of Botox for headache treatment.

You may also be interested in...



FDA Looks To States For Warning Letter Help; Policy Change Boosts Enforcement

The pieces are in place for states to contribute evidence or data to FDA that can be used to build compliance actions

FDA Looks To States For Warning Letter Help; Policy Change Boosts Enforcement

The pieces are in place for states to contribute evidence or data to FDA that can be used to build compliance actions

Beauty Is A Pain: FDA Cites Latisse Web Site For Implying Drug Is A Cosmetic

Allergan's consumer Web site for its eyelash growth drug, Latisse,certainly caught FDA's eye, leading the agency to issue a Sept. 10 "untitled" letter that cautions against promoting a drug like a cosmetic

Related Content

Topics

UsernamePublicRestriction

Register

PS068697

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel